NIH, NCI budgets up by more than 5% in FY23; FDA gets more robust accelerated approval authority

Argonne National Laboratory receives $22M from ARPA-H to accelerate cancer therapy, vaccine discoveries using AI

The U.S. Department of Energy’s Argonne National Laboratory will use its world-leading capabilities in artificial intelligence and high-performance computing to research novel ways to fight cancer and advance vaccine discovery.

November 22, 2024

Vol.50 No.44

In Brief

University of Cincinnati receives $2.3M from NCI to visualize CAR T cells within the body

The University of Cincinnati Cancer Center was granted $2.3 million from NCI to develop a technique to visualize where genetically modified immune cells go in the body after being administered to patients with cancer.

November 22, 2024

Vol.50 No.44

White House

As Trump’s HHS pick, RFK Jr. stands to honor or squander the Kennedy legacy in cancer

President-elect Donald Trump said he would nominate Robert F. Kennedy Jr. to the post of secretary of the Department of Health and Human Services, placing the vaccine skeptic in charge of a vast empire of research, engineering, regulatory, and health care agencies.

NCI renews IU Simon Comprehensive Cancer Center’s designation

NCI renewed the Comprehensive Cancer Center designation to the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, awarding it a five-year, $14.2 million grant.

November 15, 2024

Vol.50 No.43

In Brief

Bertagnolli, Goldberg, Gunn, Brundage, and Theiler receive awards at Alliance fall meeting

NIH Director Monica M. Bertagnolli delivered the Charles G. Moertel Lecture at the Fall Group Meeting of the Alliance for Clinical Trials in Oncology. The meeting took place Oct. 30-Nov. 1.

November 15, 2024

Vol.50 No.43

Clinical

NCI’s myeloMATCH will use biomarkers to match patients with myeloid cancer to trials

NCI has launched a second-generation precision medicine clinical trial called Myeloid Malignancies Molecular Analysis for Therapy Choice, or myeloMATCH, a trial focused on acute myeloid leukemia and myelodysplastic syndromes.

October 25, 2024

Vol.50 No.40

By Claire Marie Porter

NIH, NCI budgets up by more than 5% in FY23; FDA gets more robust accelerated approval authority

YOU MAY BE INTERESTED IN

Argonne National Laboratory receives $22M from ARPA-H to accelerate cancer therapy, vaccine discoveries using AI

University of Cincinnati receives $2.3M from NCI to visualize CAR T cells within the body

As Trump’s HHS pick, RFK Jr. stands to honor or squander the Kennedy legacy in cancer

NCI renews IU Simon Comprehensive Cancer Center’s designation

Bertagnolli, Goldberg, Gunn, Brundage, and Theiler receive awards at Alliance fall meeting

NCI’s myeloMATCH will use biomarkers to match patients with myeloid cancer to trials

Renew today!

Subscriber content

Never miss an issue!

Login